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C
ancer biologists are constantly 
hunting for tumor-speciﬁ  c  anti-
gens that can be targeted for 
monoclonal antibody therapy. Work by 
Andrea Schietinger, Mary Philip, Hans 
Schreiber, and colleagues (University of 
Chicago, IL) reveals that you don’t need 
a mutation in the antigen itself to make it 
tumor speciﬁ  c. Incorrect posttranslational 
modiﬁ  cation will do.
The group identiﬁ  ed a mutation-free antigen in 
a spontaneous murine ﬁ  brosarcoma, called Ag104A. 
Mice with this tumor produce a high-afﬁ  nity, highly 
speciﬁ  c antibody against what the group now identi-
ﬁ  es as a transmembrane protein called OTS8. Although 
OTS8 is widely expressed, the antibody was only 
reactive to OTS8 from the Ag104A tumor.
Tumor-derived OTS8 was a different molecular 
weight than its nonantigenic counterpart yet, to the 
group’s surprise, was not mutated. The different 
molecular weight was instead due to altered glyco-
sylation. Whereas normal OTS8 contained large 
sugar moieties, tumor-derived OTS8 predominantly 
contained a smaller monosaccharide called Tn. This 
novel combination of Tn and OTS8 created the tumor-
speciﬁ   c antigen. The defective glycosylation was 
due to a mutation in a chaperone protein called 
Cosmc, which controls the activity of a galactosyl-
transferase enzyme.
A single mutation that leads to defective glyco-
sylation provides the potential for multiple possible 
antigens, and, encouragingly, Cosmc mutations do 
not appear to be limited to just one type of tumor. In 
addition to previously identiﬁ  ed Cosmc mutations in a 
human colon cancer and a T cell leukemia cell line, 
the team discovered that Cosmc was also mutated in 
a murine neuroblastoma that also overexpressed Tn.
Certain human cancers are known to over-
express Tn. If patients with these cancers have Cosmc 
mutations, it would strongly suggest that the tumor 
cells express many incorrectly glycosylated proteins 
that are potential tumor-speciﬁ  c targets for therapy.
Reference: Schietinger, A., et al. 2006. Science. 
314:304–308.
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Tumor-derived OTS8 is not mutated 
but is a lower molecular weight 
due to aberrant glycosylation.
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Centrosomes deliver the death blow
J
ust as a deadly martial arts master channels his inner chi to 
deliver a fatal strike, cytotoxic T cells (CTLs) channel their toxic 
secretory granules to strike an infected target cell. New work by 
Jane Stinchcombe, Gillian Griffi  ths, and colleagues (Sir William Dunn 
School of Pathology, Oxford, UK) reveals that centrosomes do this 
channeling, going right to the plasma membrane to deliver their secretory 
granule death blows.
A CTL targets an infected cell by making transitory contact via an 
immunological synapse. Lytic protein–containing secretory granules 
are then released at the synapse to kill the target. Traffi  cking of the 
granules to the synapse was known to require transport along 
microtubules, but just how granules were delivered was unknown.
The general assumption was that CTLs would deliver their 
secretory granules in the same way that melanocytes deliver pigment 
for secretion—by transporting it along microtubules, transferring it 
to the actin cytoskeleton, and then delivering it to the membrane. Griffi  ths’s group thus looked at actin 
in CTLs, but found that it is completely cleared away from the synapse.
The authors found that secretory granule movement toward the minus ends of microtubules was suffi  cient 
for killing target cells. Granules thus move toward the centrosome, which associates with microtubule 
minus ends, not toward plus ends at the plasma membrane.
The team observed that the centrosome itself associates with the membrane in a large number of synapses. 
They hypothesize that the action of clearing the actin might, via actins’ attachment to microtubules, pull the 
centrosome close enough to the synapse membrane to send out the granules directly. Griffi  ths proposes that 
such direct delivery, without the need for transfer to the actin cytoskeleton, might also explain how the same 
CTL can engage and disengage synapses rapidly to kill multiple target cells, much like Bruce Lee rapidly 
defeats multiple opponents when surrounded.
Reference: Stinchcombe, J.C., et al. 2006. Nat. Cell Biol. doi:10.1038/nature05071.
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Centrosomes (red) go right to the membrane (green) to 
deliver toxic granules at the synapse